Stillwater Capital Advisors’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$23.1M Sell
179,429
-761
-0.4% -$89.1K 2.35% 15
2026
Q1
$21.7M Sell
180,190
-2,318
-1% -$268K 2.47% 17
2025
Q4
$19.2M Buy
182,508
+880
+0.5% +$82.6K 2.06% 20
2025
Q3
$15.2M Sell
181,628
-893
-0.5% -$73.6K 1.72% 25
2025
Q2
$14.4M Buy
182,521
+1,088
+0.6% +$86.5K 1.84% 24
2025
Q1
$16.3M Sell
181,433
-564
-0.3% -$52.7K 2.27% 20
2024
Q4
$18.1M Buy
181,997
+1,659
+0.9% +$171K 2.24% 17
2024
Q3
$20.5M Sell
180,338
-2,146
-1% -$255K 2.65% 10
2024
Q2
$22.6M Sell
182,484
-2,565
-1% -$330K 3.15% 8
2024
Q1
$24.4M Sell
185,049
-865
-0.5% -$107K 3.62% 6
2023
Q4
$20.3M Sell
185,914
-844
-0.5% -$87.6K 3.25% 7
2023
Q3
$19.2M Sell
186,758
-168
-0.1% -$18.1K 3.5% 7
2023
Q2
$21.6M Sell
186,926
-684
-0.4% -$77.7K 3.81% 6
2023
Q1
$20M Sell
187,610
-4,266
-2% -$461K 3.88% 4
2022
Q4
$21.3M Sell
191,876
-4,393
-2% -$449K 4.49% 3
2022
Q3
$16.9M Sell
196,269
-13,097
-6% -$1.17M 3.86% 5
2022
Q2
$19.1M Buy
209,366
+2,170
+1% +$192K 3.55% 7
2022
Q1
$17M Sell
207,196
-5,291
-2% -$417K 2.73% 13
2021
Q4
$16.3M Sell
212,487
-1,763
-0.8% -$140K 2.48% 16
2021
Q3
$16.1M Sell
214,250
-1,100
-0.5% -$83.7K 2.65% 15
2021
Q2
$16.7M Sell
215,350
-10,464
-5% -$778K 2.77% 14
2021
Q1
$16.6M Sell
225,814
-83
-0% -$6.12K 3.01% 10
2020
Q4
$17.6M Sell
225,897
-1,164
-0.5% -$89K 3.38% 6
2020
Q3
$18M Sell
227,061
-1,193
-0.5% -$93.4K 3.92% 5
2020
Q2
$16.8M Buy
228,254
+1,502
+0.7% +$113K 4.06% 5
2020
Q1
$16.6M Sell
226,752
-711
-0.3% -$55.9K 4.9% 4
2019
Q4
$19.7M Buy
227,463
+899
+0.4% +$73.8K 4.46% 4
2019
Q3
$18.2M Sell
226,564
-3,468
-2% -$278K 4.62% 4
2019
Q2
$18.4M Sell
230,032
-21,105
-8% -$1.62M 4.55% 3
2019
Q1
$19.9M Sell
251,137
-6,050
-2% -$452K 4.34% 3
2018
Q4
$18.8M Sell
257,187
-3,324
-1% -$235K 4.68% 2
2018
Q3
$17.6M Buy
260,511
+2,357
+0.9% +$150K 3.66% 5
2018
Q2
$15M Sell
258,154
-3,234
-1% -$182K 3.57% 6
2018
Q1
$13.6M Buy
261,388
+13,218
+5% +$714K 3.27% 6
2017
Q4
$13.3M Buy
248,170
+39,430
+19% +$2.19M 3.13% 12
2017
Q3
$12.8M Buy
208,740
+3,966
+2% +$240K 3.3% 8
2017
Q2
$12.5M Buy
204,774
+1,619
+0.8% +$98.6K 3.17% 9
2017
Q1
$12.3M Sell
203,155
-3,080
-1% -$187K 3.28% 8
2016
Q4
$11.6M Buy
206,235
+65
+0% +$3.8K 3.1% 12
2016
Q3
$12.3M Sell
206,170
-2,252
-1% -$132K 3.58% 5
2016
Q2
$11.5M Buy
208,422
+237
+0.1% +$12.6K 3.42% 8
2016
Q1
$10.5M Buy
208,185
+4,422
+2% +$217K 3.11% 15
2015
Q4
$10.3M Sell
203,763
-5,462
-3% -$275K 3.15% 14
2015
Q3
$9.86M Sell
209,225
-389
-0.2% -$20.7K 3.36% 14
2015
Q2
$11.4M Buy
209,614
+2,008
+1% +$113K 3.3% 7
2015
Q1
$11.4M Buy
207,606
+3,438
+2% +$195K 3.46% 7
2014
Q4
$11.1M Buy
204,168
+6,628
+3% +$369K 3.32% 9
2014
Q3
$11.2M Sell
197,540
-51
-0% -$2.86K 3.74% 3
2014
Q2
$10.9M Sell
197,591
-1,052
-0.5% -$57.4K 3.71% 3
2014
Q1
$10.8M Sell
198,643
-1,245
-0.6% -$64.5K 3.91% 1
2013
Q4
$9.55M Buy
199,888
+51,834
+35% +$2.37M 3.7% 6
2013
Q3
$6.73M Sell
148,054
-1,158
-0.8% -$52.9K 3.97% 5
2013
Q2
$6.61M Buy
+149,212
New +$6.66M 4.09% 5

Other funds holding MRK

Stillwater Capital Advisors's MRK Position: Q2 2026 in Review

Stillwater Capital Advisors reduced its Merck (MRK) stake by 0.42% in Q2 2026, selling an estimated $89.1K and leaving 179,429 shares worth $23.1M. The position accounts for 2.35% of the portfolio, ranked #15.

Stillwater Capital Advisors first reported a position in MRK in Q2 2013 and has held it in 53 quarters since. The position peaked at $24.4M in Q1 2024. 1,145 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Stillwater Capital Advisors held 179,429 shares of Merck worth $23.1M as of Q2 2026.
  • Stillwater Capital Advisors sold 761 Merck shares in Q2 2026, an estimated $89.1K.
  • Merck made up 2.35% of Stillwater Capital Advisors's portfolio in Q2 2026, its #15 holding.
  • Stillwater Capital Advisors first reported a position in Merck in Q2 2013 and has held it in 53 quarters since.
  • Stillwater Capital Advisors's Merck position peaked at $24.4M in Q1 2024.
  • 1,145 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Stillwater Capital Advisors's 13F filing for Q2 2026, filed 23 Jul 2026.